Refractory period (sex) for treating sexual dysfunction. Sildenafil, used in the treatment of erectile dysfunction, was found in one scientific study to have caused "a decreased postejaculatory erectile refractory time (3.2 ± 0.7 vs. 6.4 ± 0.7 minutes)" in men diagnosed with premature ejaculation. It is additionally proposed that the gonadotropin inhibitory hormone (GnIH), which is considered to inhibit the hypothalamic-pituitary-gonadal axis and sexual functions causes refractoriness of the post-ejaculatory refractory period. This hypothesis also supports the increase of oxytocin and prolactin after orgasm in accordance with the previous studies. One alternative theory explains the male refractory period in terms of a peripheral
Corticotropin-releasing hormone receptor 2 Corticotropin-releasing hormone receptor 2 Corticotropin-releasing hormone receptor 2 (CRHR2) is a protein, also known by the IUPHAR-recommended name CRF, that is encoded by the CRHR2 gene and occurs on the surfaces of some mammalian cells. CRF receptors are type 2 G protein-coupled receptors for corticotropin-releasing hormone (CRH) that are resident in the plasma membranes of hormone-sensitive cells. CRH, a peptide of 41 amino acids synthesized in the hypothalamus, is the principal neuroregulator of the hypothalamic-pituitary-adrenal axis, signaling via guanine nucleotide-binding proteins (G proteins) and downstream effectors such as adenylate cyclase. The CRF receptor is a multi-pass membrane protein with a